{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:14:30Z","timestamp":1791274470495,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteosarcoma (OS) is characterized by high malignancy and profound metabolic reprogramming, yet the upstream regulators of its lipid metabolic adaptations remain largely elusive. Here, we report that RHBDL2 is significantly overexpressed in OS tissues, correlating with advanced clinical stage and poor patient prognosis. Mechanistically, multi-omics and structural analyses reveal that RHBDL2 functions as a non-proteolytic scaffold to stabilize the deubiquitinase USP3. This interaction is mediated by a compact hydrophobic core anchored by the Val245 residue of RHBDL2 and occurs independently of its protease activity. Stabilized USP3 subsequently prevents the proteasomal degradation of Palmitoyl-Protein Thioesterase 1 (PPT1) through deubiquitination. We further identify PPT1 as a metabolic rheostat that fuels OS malignancy by orchestrating FASN-dependent de novo lipogenesis, a requirement that can be partially bypassed by exogenous lipid supplementation. This RHBDL2-USP3-PPT1 axis promotes OS cell proliferation, migration, and epithelial-mesenchymal transition while suppressing apoptosis. Pharmacological screening identified Epigallocatechin gallate (EGCG) as a potent inhibitor that competitively disrupts the RHBDL2-USP3 interaction interface, thereby suppressing the downstream lipogenic program and inhibiting tumor growth and bone destruction in vivo. Collectively, our findings delineate a novel signaling cascade linking post-translational protein stabilization to metabolic adaptation, highlighting the RHBDL2-USP3 structural interface as a promising therapeutic vulnerability in osteosarcoma.<\/jats:p>","DOI":"10.1038\/s41419-026-08788-w","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T16:34:54Z","timestamp":1777048494000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RHBDL2 drives lipid metabolic reprogramming in osteosarcoma via USP3-mediated deubiquitination of PPT1"],"prefix":"10.1038","volume":"17","author":[{"given":"Li","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1955-5116","authenticated-orcid":false,"given":"Kewei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"8788_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100652","volume":"49","author":"X Yuan","year":"2024","unstructured":"Yuan X, Yu B, Ding H, Li H, Wang Q, Lin L, et al. Novel lipid metabolism factor HIBCH inhibitor synergizes with doxorubicin to suppress osteosarcoma growth and impacts clinical prognosis in osteosarcoma patients. J Bone Oncol. 2024;49:100652.","journal-title":"J Bone Oncol"},{"key":"8788_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41571-021-00519-8","volume":"18","author":"J Gill","year":"2021","unstructured":"Gill J, Gorlick R. Advancing therapy for osteosarcoma. Nat Rev Clin Oncol. 2021;18:609\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"8788_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20201606","volume":"218","author":"X Bian","year":"2021","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218:1.","journal-title":"J Exp Med"},{"key":"8788_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02746-0","volume":"22","author":"G Zhu","year":"2022","unstructured":"Zhu G, Xia Y, Zhao Z, Li A, Li H, Xiao T. LncRNA XIST from the bone marrow mesenchymal stem cell derived exosome promotes osteosarcoma growth and metastasis through miR-655\/ACLY signal. Cancer Cell Int. 2022;22:330.","journal-title":"Cancer Cell Int"},{"key":"8788_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/molecules27092741","volume":"27","author":"H Fan","year":"2022","unstructured":"Fan H, Huang W, Guo Y, Ma X, Yang J. Alpha-linolenic acid suppresses proliferation and invasion in osteosarcoma cells via inhibiting fatty acid synthase. Molecules. 2022;27:9.","journal-title":"Molecules"},{"key":"8788_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05379-3","volume":"13","author":"S Chen","year":"2022","unstructured":"Chen S, Cai K, Zheng D, Liu Y, Li L, He Z, et al. RHBDL2 promotes the proliferation, migration, and invasion of pancreatic cancer by stabilizing the N1ICD via the OTUD7B and activating the Notch signaling pathway. Cell Death Dis. 2022;13:945.","journal-title":"Cell Death Dis"},{"key":"8788_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-78713-8","volume":"14","author":"Z Che","year":"2024","unstructured":"Che Z, Jin W, Wu Y, Li H, Liang P. Rhomboid-like 2 correlated with TME infiltration inhibits cuproptosis-related genes and drives malignant phenotype in clear cell renal cell carcinoma. Sci Rep. 2024;14:27053.","journal-title":"Sci Rep"},{"key":"8788_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-89948-4","volume":"15","author":"M Hu","year":"2025","unstructured":"Hu M, Tao P, Wang Y, Zhu C, Ma Y, Liu X, et al. Knockdown of CCNB2 inhibits the tumorigenesis of gastric cancer by regulation of the PI3K\/Akt pathway. Sci Rep. 2025;15:5703.","journal-title":"Sci Rep"},{"key":"8788_CR9","doi-asserted-by":"publisher","first-page":"e3001590","DOI":"10.1371\/journal.pbio.3001590","volume":"20","author":"EL Gorenberg","year":"2022","unstructured":"Gorenberg EL, Massaro Tieze S, Yucel B, Zhao HR, Chou V, Wirak GS, et al. Identification of substrates of palmitoyl protein thioesterase 1 highlights roles of depalmitoylation in disulfide bond formation and synaptic function. PLoS Biol. 2022;20:e3001590.","journal-title":"PLoS Biol"},{"key":"8788_CR10","doi-asserted-by":"publisher","first-page":"BSR20230067","DOI":"10.1042\/BSR20230067","volume":"43","author":"W Tian","year":"2023","unstructured":"Tian W, Li C, Ren J, Li P, Zhao J, Li S, et al. Identification of PPT1 as a lysosomal core gene with prognostic value in hepatocellular carcinoma. Biosci Rep. 2023;43:BSR20230067.","journal-title":"Biosci Rep"},{"key":"8788_CR11","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/15548627.2024.2403152","volume":"21","author":"MAS Crissey","year":"2025","unstructured":"Crissey MAS, Versace A, Bhardwaj M, Jain V, Liu S, Singh A, et al. Divergent effects of acute and chronic PPT1 inhibition in melanoma. Autophagy. 2025;21:394\u2013406.","journal-title":"Autophagy"},{"key":"8788_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11523-023-01019-8","volume":"19","author":"E Bestion","year":"2024","unstructured":"Bestion E, Rachid M, Tijeras-Raballand A, Roth G, Decaens T, Ansaldi C, et al. Ezurpimtrostat, A palmitoyl-protein thioesterase-1 inhibitor, combined with PD-1 inhibition provides CD8(+) lymphocyte repopulation in hepatocellular carcinoma. Target Oncol. 2024;19:95\u2013106.","journal-title":"Target Oncol"},{"key":"8788_CR13","doi-asserted-by":"publisher","first-page":"e006655","DOI":"10.1136\/jitc-2022-006655","volume":"11","author":"J Weng","year":"2023","unstructured":"Weng J, Liu S, Zhou Q, Xu W, Xu M, Gao D, et al. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma. J Immunother Cancer. 2023;11:e006655.","journal-title":"J Immunother Cancer"},{"key":"8788_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103376","volume":"77","author":"Y Ma","year":"2024","unstructured":"Ma Y, Yuan X, Wei A, Li X, Patar A, Su S, et al. Enhancing Gpx1 palmitoylation to inhibit angiogenesis by targeting PPT1. Redox Biol. 2024;77:103376.","journal-title":"Redox Biol"},{"key":"8788_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06624-7","volume":"15","author":"A Li","year":"2024","unstructured":"Li A, Wang S, Nie J, Xiao S, Xie X, Zhang Y, et al. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K\/AKT signaling pathway. Cell Death Dis. 2024;15:235.","journal-title":"Cell Death Dis"},{"key":"8788_CR16","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1016\/j.molcel.2021.10.025","volume":"81","author":"AG Grieve","year":"2021","unstructured":"Grieve AG, Yeh YC, Chang YF, Huang HY, Zarcone L, Breuning J, et al. Conformational surveillance of Orai1 by a rhomboid intramembrane protease prevents inappropriate CRAC channel activation. Mol Cell. 2021;81:4784\u201398.e7.","journal-title":"Mol Cell"},{"key":"8788_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s11658-023-00460-x","volume":"28","author":"HN Sun","year":"2023","unstructured":"Sun HN, Ren CX, Lee DH, Wang WH, Guo XY, Hao YY, et al. PRDX1 negatively regulates bleomycin-induced pulmonary fibrosis via inhibiting the epithelial-mesenchymal transition and lung fibroblast proliferation in vitro and in vivo. Cell Mol Biol Lett. 2023;28:48.","journal-title":"Cell Mol Biol Lett"},{"key":"8788_CR18","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13560","volume":"57","author":"H Xu","year":"2024","unstructured":"Xu H, Wang J, Al-Nusaif M, Ma H, Le W. CCL2 promotes metastasis and epithelial-mesenchymal transition of non-small cell lung cancer via PI3K\/Akt\/mTOR and autophagy pathways. Cell Prolif. 2024;57:e13560.","journal-title":"Cell Prolif"},{"key":"8788_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02180-y","volume":"23","author":"X Zhou","year":"2024","unstructured":"Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, et al. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K\/AKT activation in colorectal cancer. Mol Cancer. 2024;23:282.","journal-title":"Mol Cancer"},{"key":"8788_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404229","volume":"11","author":"L Li","year":"2024","unstructured":"Li L, Zhang X, Xu G, Xue R, Li S, Wu S, et al. Transcriptional regulation of de novo lipogenesis by SIX1 in liver cancer cells. Adv Sci (Weinh). 2024;11:e2404229.","journal-title":"Adv Sci (Weinh)"},{"key":"8788_CR21","doi-asserted-by":"publisher","first-page":"e164596","DOI":"10.1172\/JCI164596","volume":"133","author":"M Bhardwaj","year":"2023","unstructured":"Bhardwaj M, Lee JJ, Versace AM, Harper SL, Goldman AR, Crissey MAS, et al. Lysosomal lipid peroxidation regulates tumor immunity. J Clin Invest. 2023;133:e164596.","journal-title":"J Clin Invest"},{"key":"8788_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14612","volume":"8","author":"MB Bagh","year":"2017","unstructured":"Bagh MB, Peng S, Chandra G, Zhang Z, Singh SP, Pattabiraman N, et al. Misrouting of v-ATPase subunit V0a1 dysregulates lysosomal acidification in a neurodegenerative lysosomal storage disease model. Nat Commun. 2017;8:14612.","journal-title":"Nat Commun"},{"key":"8788_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-03206-1","volume":"14","author":"J Tong","year":"2024","unstructured":"Tong J, Gao J, Qi Y, Gao Z, Wang Q, Liu Y, et al. GABA(A)R-PPT1 palmitoylation homeostasis controls synaptic transmission and circuitry oscillation. Transl Psychiatry. 2024;14:488.","journal-title":"Transl Psychiatry"},{"key":"8788_CR24","doi-asserted-by":"publisher","first-page":"e40316","DOI":"10.7554\/eLife.40316","volume":"8","author":"KP Koster","year":"2019","unstructured":"Koster KP, Francesconi W, Berton F, Alahmadi S, Srinivas R, Yoshii A. Developmental NMDA receptor dysregulation in the infantile neuronal ceroid lipofuscinosis mouse model. Elife. 2019;8:e40316.","journal-title":"Elife"},{"key":"8788_CR25","doi-asserted-by":"publisher","first-page":"bqac213","DOI":"10.1210\/endocr\/bqac213","volume":"164","author":"X Kang","year":"2023","unstructured":"Kang X, Ma X, Li H, Jin X, Gao X, Feng D, et al. Neuropeptide Y promotes mTORC1 to regulate chondrocyte proliferation and hypertrophy. Endocrinology. 2023;164:bqac213.","journal-title":"Endocrinology"},{"key":"8788_CR26","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1007\/s11357-024-01143-x","volume":"46","author":"M Kitami","year":"2024","unstructured":"Kitami M, Kaku M, Thant L, Maeda T. A loss of primary cilia by a reduction in mTOR signaling correlates with age-related deteriorations in condylar cartilage. Geroscience. 2024;46:5995\u20136007.","journal-title":"Geroscience"},{"key":"8788_CR27","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1038\/s42255-022-00706-6","volume":"4","author":"AM Hosios","year":"2022","unstructured":"Hosios AM, Wilkinson ME, McNamara MC, Kalafut KC, Torrence ME, Asara JM, et al. mTORC1 regulates a lysosome-dependent adaptive shift in intracellular lipid species. Nat Metab. 2022;4:1792\u2013811.","journal-title":"Nat Metab"},{"key":"8788_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47311-7","volume":"15","author":"C Ho H\u2019ng","year":"2024","unstructured":"Ho H\u2019ng C, Amarasinghe SL, Zhang B, Chang H, Qu X, Powell DR, et al. Compensatory growth and recovery of cartilage cytoarchitecture after transient cell death in fetal mouse limbs. Nat Commun. 2024;15:2940.","journal-title":"Nat Commun"},{"key":"8788_CR29","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1080\/10408398.2022.2104805","volume":"64","author":"Y Ntamo","year":"2024","unstructured":"Ntamo Y, Jack B, Ziqubu K, Mazibuko-Mbeje SE, Nkambule BB, Nyambuya TM, et al. Epigallocatechin gallate as a nutraceutical to potentially target the metabolic syndrome: novel insights into therapeutic effects beyond its antioxidant and anti-inflammatory properties. Crit Rev Food Sci Nutr. 2024;64:87\u2013109.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"8788_CR30","doi-asserted-by":"publisher","first-page":"6546","DOI":"10.1080\/10408398.2023.2170972","volume":"64","author":"S Zhang","year":"2024","unstructured":"Zhang S, Mao B, Cui S, Zhang Q, Zhao J, Tang X, et al. Absorption, metabolism, bioactivity, and biotransformation of epigallocatechin gallate. Crit Rev Food Sci Nutr. 2024;64:6546\u201366.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"8788_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138734","volume":"290","author":"J Ma","year":"2025","unstructured":"Ma J, Tan Z, Wei X, Tian Z, Wang VY, Wang E, et al. Electrospray whey protein-polysaccharide microcapsules co-encapsulating Lactiplantibacillus plantarum and EGCG: Enhanced probiotic viability and antioxidant activity. Int J Biol Macromol. 2025;290:138734.","journal-title":"Int J Biol Macromol"},{"key":"8788_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.job.2022.05.006","volume":"64","author":"S Yoshida","year":"2022","unstructured":"Yoshida S, Inaba H, Nomura R, Nakano K, Matsumoto-Nakano M. Green tea catechins inhibit Porphyromonas gulae LPS-induced inflammatory responses in human gingival epithelial cells. J Oral Biosci. 2022;64:352\u20138.","journal-title":"J Oral Biosci"},{"key":"8788_CR33","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jare.2024.04.034","volume":"70","author":"M Nasb","year":"2025","unstructured":"Nasb M, Li F, Dayoub L, Wu T, Wei M, Chen N. Bridging the gap: integrating exercise mimicry into chronic disease management through suppressing chronic inflammation. J Adv Res. 2025;70:307\u201322.","journal-title":"J Adv Res"},{"key":"8788_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113596","volume":"381","author":"WY Pan","year":"2025","unstructured":"Pan WY, Weng PW, Wu SH, Hsiao CH, Jheng PR, Nguyen HN, et al. Intranasal delivery of epigallocatechin gallate-laden platelet extracellular vesicles for mitigating retinal glaucoma. J Control Release. 2025;381:113596.","journal-title":"J Control Release"},{"key":"8788_CR35","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/molecules29061373","volume":"29","author":"WH Talib","year":"2024","unstructured":"Talib WH, Awajan D, Alqudah A, Alsawwaf R, Althunibat R, Abu AlRoos M, et al. Targeting cancer hallmarks with epigallocatechin gallate (EGCG): mechanistic basis and therapeutic targets. Molecules. 2024;29:1373.","journal-title":"Molecules"},{"key":"8788_CR36","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s43556-024-00240-9","volume":"5","author":"M Alam","year":"2024","unstructured":"Alam M, Gulzar M, Akhtar MS, Rashid S, Zulfareen, Tanuja, et al. Epigallocatechin-3-gallate therapeutic potential in human diseases: molecular mechanisms and clinical studies. Mol Biomed. 2024;5:73.","journal-title":"Mol Biomed"},{"key":"8788_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-03069-0","volume":"22","author":"K Wang","year":"2024","unstructured":"Wang K, Geng S, Wang F, Fang B, Qian H, Li Y, et al. Natural epigallocatechin-3-gallocarboxylate nanoformulation loaded doxorubicin to construct a novel and low cardiotoxicity chemotherapeutic drug for high-efficiency breast cancer therapy. J Nanobiotechnol. 2024;22:793.","journal-title":"J Nanobiotechnol"},{"key":"8788_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-024-02815-8","volume":"22","author":"P Pradeep Prabhu","year":"2024","unstructured":"Pradeep Prabhu P, Mohanty B, Lobo CL, Balusamy SR, Shetty A, Perumalsamy H, et al. Harnessing the nutriceutics in early-stage breast cancer: mechanisms, combinational therapy, and drug delivery. J Nanobiotechnol. 2024;22:574.","journal-title":"J Nanobiotechnol"},{"key":"8788_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156512","volume":"139","author":"Z Dong","year":"2025","unstructured":"Dong Z, Wu J, He L, Xie C, Geng S, Wu J, et al. EGCG inhibits tobacco smoke-promoted proliferation of lung cancer cells through targeting CCL5. Phytomedicine. 2025;139:156512.","journal-title":"Phytomedicine"},{"key":"8788_CR40","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/jbmr.4036","volume":"35","author":"CH Chen","year":"2020","unstructured":"Chen CH, Lai CH, Hong YK, Lu JM, Lin SY, Lee TC, et al. Thrombomodulin functional domains support osteoblast differentiation and bone healing in diabetes in mice. J Bone Min Res. 2020;35:1812\u201323.","journal-title":"J Bone Min Res"},{"key":"8788_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/187152511796196498","volume":"9","author":"N Clere","year":"2011","unstructured":"Clere N, Faure S, Martinez MC, Andriantsitohaina R. Anticancer properties of flavonoids: roles in various stages of carcinogenesis. Cardiovasc Hematol Agents Med Chem. 2011;9:62\u201377.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"8788_CR42","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1158\/0008-5472.CAN-08-3978","volume":"69","author":"IA Siddiqui","year":"2009","unstructured":"Siddiqui IA, Adhami VM, Bharali DJ, Hafeez BB, Asim M, Khwaja SI, et al. Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009;69:1712\u20136.","journal-title":"Cancer Res"},{"key":"8788_CR43","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/embor.2011.50","volume":"12","author":"C Adrain","year":"2011","unstructured":"Adrain C, Strisovsky K, Zettl M, Hu L, Lemberg MK, Freeman M. Mammalian EGF receptor activation by the rhomboid protease RHBDL2. EMBO Rep. 2011;12:421\u20137.","journal-title":"EMBO Rep"},{"key":"8788_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms20235958","volume":"20","author":"C Battistini","year":"2019","unstructured":"Battistini C, Rehman M, Avolio M, Arduin A, Valdembri D, Serini G, et al. Rhomboid-Like-2 intramembrane protease mediates metalloprotease-independent regulation of cadherins. Int J Mol Sci. 2019;20:23.","journal-title":"Int J Mol Sci"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08788-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08788-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:01:57Z","timestamp":1780891317000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08788-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8788"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08788-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"29 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All clinical data and specimens involved in this study were obtained with written informed consent from the patients and approved by the Ethics Committee of Wuhan Polytechnic University (BME-2025-1-14). All animal experiments were conducted in accordance with the regulations of the Ethics Committee of Wuhan Polytechnic University (BME-2025-2-11).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"548"}}